Ultra-processed Food Consumption, Gut Microbiota, and Glucose Homeostasis in Mid-life Adults
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Change in insulin sensitivity from baseline to 6-weeks post high or no UPF diet
Study Overview
Brief Summary
Advancing age is associated with gut dysbiosis, low-grade chronic inflammation, progressive insulin resistance, and increased risk of type 2 diabetes (T2D). Prediabetes is present in 45-50% of middle-aged/older adults, and declines in glucose tolerance are evident in the third or fourth decade of life. Thus, there is an urgent need to identify new approaches for the prevention of type 2 diabetes among middle-aged adults. Observational research has linked intake of ultra-processed foods (UPF), which comprise ~60% of total energy intake in US adults, with increased risk of T2D. Ex vivo and animal research suggests that components of UPF alter gut microbiota composition and initiate a cascade of events leading to intestinal inflammation and impaired glycemic control. Whether mid-life adults (aged 45-65 yrs) are susceptible to the adverse impact of UPF consumption on glucose homeostasis is unknown. The overall objective of this study is to establish proof-of-concept for an impairment in glucose homeostasis following increases in UPF consumption in mid-life adults, in order to conduct a larger, more comprehensive and mechanistic trial in the future. In addition, changes in gut microbial composition and function, intestinal inflammation and permeability, serum endotoxin concentrations, and inflammatory cytokines as potential mechanisms by which UPF consumption influences glucose homeostasis will be investigated.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Weight stable for previous 6 months
- •Sedentary to recreationally active
- •No plans to gain/lose weight or change physical activity level
- •Willing to pick up food daily and consume foods provided for an 8-week period
- •Verbal and written informed consent
- •Approval by Medical Director
- •Estrogen or testosterone usage is acceptable, if on stable dose for >6 months
Exclusion Criteria
- •BMI >35 kg/m2
- •Diabetes or diabetes medication
- •Antibiotic, prebiotic or prebiotic use in prior 3 months
- •TCHOL >6.2 mmol/L; TG >4.5 mmol/L
- •Blood pressure (BP) > 159/99 mmHg (Stable BP on antihypertensive medications used for >6 months is acceptable)
- •Diagnosed inflammatory bowel disease
- •Past or current heart diseases, stroke, respiratory disease, endocrine or metabolic disease, or hematological-oncological disease
- •Vegetarian or vegan
- •Pregnant or plans to become pregnant
- •Food allergies or aversions
- •3 or fewer stools per week or regular laxative use
Arms & Interventions
HIgh UPF (Ultra-processed foods)
Participants will consume a diet containing 81% total energy from UPF for 6 weeks
Intervention: HIgh UPF controlled diet (Other)
No UPF
Participants will consume a diet containing 0% total energy from UPF for 6 weeks
Intervention: No UPF controlled diet (Other)
Outcomes
Primary Outcomes
Change in insulin sensitivity from baseline to 6-weeks post high or no UPF diet
Time Frame: 2 timepoints (standardized diet lead-in [baseline]), 6-weeks post high or no UPF diet, 2-hour test in laboratory
Insulin sensitivity assessed using a 2-hour oral glucose tolerance test (75g glucose load). Blood will be collected at baseline (fasting), and thereafter at 30-minute intervals (5 total measurements in 2 hours) at baseline and post 6-weeks high or no UPF diet.
Secondary Outcomes
- Change in 24-hour glucose control (24-hour mean) from baseline to 6-weeks post high or no UPF diet(6-day measurement during free-living, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
- Change in endotoxin from baseline to post 6-weeks high or no UPF diet(5-minute blood collection in the laboratory, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
- Change in 24-hour glucose control (time in range) from baseline to 6-weeks post high or no UPF diet(6-day measurement during free-living, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
- Change in 24-hour glucose control (glycemic variability [GV]) from baseline to 6-weeks post high or no UPF diet(6-day measurement during free-living, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
- Change in 24-hour glucose control (AUC) from baseline to 6-weeks post high or no UPF diet(6-day measurement during free-living, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
- Change in 24-hour glucose control (postprandial glucose) from baseline to 6-weeks post high or no UPF diet(6-day measurement during free-living, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
- Change in inflammatory cytokines from baseline to post 6-weeks high or no UPF diet(5-minute blood collection in the laboratory, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
- Change in gut microbial composition from baseline to post 6-weeks high or no UPF diet(3-day collection during free-living, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
- Change in intestinal inflammation from baseline to post 6-weeks high or no UPF diet(3-day collection during free-living, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
- Change in gut microbial function from baseline to post 6-weeks high or no UPF diet(3-day collection during free-living, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
- Change in intestinal permeability from baseline to post 6-weeks high or no UPF diet(3-day collection during free-living, 2 timepoints (baseline, 6 weeks post high or no UPF diet))
Investigators
Brenda Davy
Professor
Virginia Polytechnic Institute and State University